GSK gains Zejula, immuno-oncology pipeline in $5.1B Tesaro acquisition

Although it's inheriting a portfolio of cancer compounds from Tesaro Inc. (NASDAQ:TSRO) that fall squarely into competitive areas, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) expects to transform the candidates, including Zejula niraparib, into best-in-class therapies under Hal Barron's R&D leadership.

The pharma is acquiring Tesaro for $75 per share in a deal the partners say values Tesaro at $5.1 billion including debt. The price is a 62% premium to Tesaro’s close of $46.38 on Friday, before the deal was

Read the full 777 word article

User Sign In